The UK’s MHRA recently published its guidance on its approach to both regulating the use of AI for drug and medical devices, and how it can utilise the technology to improve its regulating
We normally only segment our hires roundup into three categories, but for the May-June double issue we had enough non-profit, professional organisation, and government hires to spin them of
The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded medicines spend; the 2019 Voluntary Scheme for Branded Medicines Pricing
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh